506 Durable disease stabilization and antitumor activity with rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, in combination with gemcitabine: a phase I and pharmacokinetic study in patients with advanced cancer
E. Calvo, E.K. Rowinksy, A.W. Tolcher, Q.S. Chu, M. Beeram, A. Mita, K. Mettinger, M. Knepper, A.D. Goetz, A. PatnaikVolume:
2
Year:
2004
Language:
english
DOI:
10.1016/s1359-6349(04)80514-7
File:
PDF, 284 KB
english, 2004